Benzoxazepine derivatives

Abstract: A benzoxazepine derivative suitable for use as a psychotropic composition having the formula: wherein A and B are both carbonyl groups, or one thereof represents a methylene group and the other a carbonyl group, R represents an aromatic group or a heterocyclic group, which may be substituted, X represents a hydrogen atom, a halogen atom, a C₁ - C₅ lower alkyl group, a C₁ - C₅ lower alkoxy group, a C₇ - C₉ arylalkoxy group, a hydroxyl group, a nitro group, or an ester group, and n is an integer of 2 to 10, or a salt thereof.

Description: The present invention relates to a benzoxazepine derivative having the formula: wherein A and B are both carbonyl groups, or one thereof represents a methylene group and the other a carbonyl group, R represents an aromatic group or a heterocyclic group which may be substituted, X represents a hydrogen atom, a halogen atom, preferably chlorine, bromine, fluorine, a C₁ - C₅ lower alkyl group, preferably a C₁ - C₃ alkyl group, a C₁ - C₅ lower alkoxy group, preferably a C₁ - C₃ alkoxy group, a C₇ - C₉ arylalkoxy group, preferably a phenylalkoxy group, a hydroxyl group, a nitro group, or an ester group, and n is an integer of 2 to 10, preferably 2 to 8, more preferably 2 to 5, and salts thereof, and to a psychotropic composition containing the same as an active ingredient as well as the intermediate compounds for the preparation of the compound (I). The novel benzoxazepine derivative having formula (I) of the present invention and its salts have a potent affinity for a serotonin receptor and an anticonflict activity, and are useful as drugs for psychotic disorders such as anxiety neurosis, phobic disorder, obsessive-compulsive disorder, psychosomatic disorder, post traumatic stress disorder, depressive neurosis, and as therapeutic drugs for diseases related to serotonergic neuron system, for example, eating disorder, climacteric disorder, and infantile autism. In the prior art, benzodiazepine type drugs, antipsychotic drugs and antidepressant drugs, are used as a therapeutic, for an anxiety neurosis, phobia, and obsessive-compulsive neurosis, but these drugs each have a problem with regard to the efficacy and side effects thereof. Particularly, benzodiazepine type drugs are primarily used for an anxiety neurosis, but since a hypnotic action, muscle relaxing action, and a continuing dependence occur, there is an urgent need for the development of specific antianxiety drugs that do not have these side effects. Various attempts have been made to solve these problems, and as a result, drugs having a selective affinity for a 5HT 1A subtype of a serotonin receptor are considered probably useful as antianxiety drugs with little side effects. Namely, buspirone, gepirone, ipsapirone and the like have been or are being developed. The above-mentioned buspirone, gepirone, and ipsapirone can partially alleviate various side effects, compared with benzodiazapine type drugs of the prior art, but can not be considered absolutely satisfactory, and there is a strong demand for antianxiety drugs having a high specificity with less side effects. A problem addressed herein is to solve the above-mentioned problems of the prior art and to provide novel compounds having a more potent affinity for a 5HT 1A receptor with a higher selectivity, which is usable as an antianxiety drug, and to provide processes to make these compounds Another aspect of this problem is to provide novel compounds useful in preparing the above-mentioned novel compounds. In accordance with the present invention, there are provided a benzoxazepine derivative having the formula (I) and a pharmacologically acceptable acid addition salt thereof, and a psychotropic composition containing the benzoxazepine derivative or the salt thereof as an active ingredient. In accordance with the present invention, there is also provided an intermediate benzoxazepine derivative having the formula (II): wherein A and B are both carbonyl groups, or one thereof represents a methylene group and the other a carbonyl group, X represents a hydrogen atom, a halogen atom, preferably chlorine, bromine, fluorine, a C₁ - C₅ lower alkyl group, preferably a C₁ - C₃ alkyl group, a C₁ - C₅ lower alkoxy group, preferably a C₁ - C₃ alkoxy group, a C₇ - C₉ arylalkoxy group, preferably a phenylalkoxy group, a hydroxyl group, a cyano group, a nitro group, or an ester group, Y represents a halogen, preferably chlorine, bromine, fluorine, and n is an integer of 2 to 10, preferably 2 to 8, more preferably 2 to 5, and salts thereof. This compound (II) may be prepared as follows. The resultant compound (II) may be condensed with a piperazine derivative to form the above-mentioned compound (I). The present inventors considered that it is most important to create a drug having a more potent affinity for a 5HT 1A receptor with a higher selectivity, to develop usable antianxiety drugs not having the drawbacks mentioned above, and thus made an intensive study of this subject and, as a result, found that a novel benzoxazepine derivative, which is the compound of the present invention, has a very potent 5HT 1A receptor affinity as well as antianxiety activity as indexed by an anticonflict activity. Compounds of the formula (I) according to the present invention maybe prepared as described below. That is, in the compounds represented by the above formula (I), the compound represented by the following formula (Ia) wherein A is a carbonyl group and B is a methylene group: may be synthesized by reacting the compound (III) of the structure shown below, and obtained by the method or similar methods as described by G.S. Sidhu, G. Thyagarajan and U.T. Bhalerao, J. Chem. Soc. (C), 969 (1966): with, for example, a dibromoalkane, to obtain the compound (IV) of the following structure: and then condensing same with a piperazine derivative in a conventional manner. Also, in the compounds represented by the above formula (I), the compound (Ib) represented by the following formula (Ib) wherein A is a methylene group and B is a carbonyl compound: may be synthesized by reacting a compound (V) having the structure shown below, obtained according to the method or similar methods described in Kost, A.N., Stankevicius, A; Khim. Geterotsiki, Soedin, 7 (9) 1288 (1971), with a dibromoalkane to obtain a compound (VI) having the structure shown below: and then condensing same with a piperazine derivative. Further, in the compounds represented by the above formula (I), the compound represented by the formula (Ic) wherein A and B are both carbonyl groups: may be synthesized by reacting a compound (VII), obtained according to the method or similar methods described in A. Cattaneo, P. Galimberti, M. Melandri: Boll. Chim. Farm., 102 , 541 (1963): with dibromobutane to obtain a compound (VIII) of the following formula: and then condensing same with a piperazine derivative. In the benzoxazepine derivative of the above formula (I) according to the present invention, R represents an aromatic group and a heterocyclic group which may be also substituted. Examples of such aromatic groups include C₆ - C₁₀ aromatic groups, specifically, a phenyl group, a naphthyl group, and these aromatic groups may be substituted with halogen atoms (chlorine, bromine, fluorine, etc.), a hydroxyl group, a C₁ - C₆ lower alkyl group, a C₁ - C₅ lower alkoxy group, a C₇ - C₉ arylalkoxy group , a cyano group, a nitro group, an amino group, an amide group, an ester group (e.g., COO·C₁ - C₅ lower alkyl group), a trifluoromethyl group etc. Further, the heterocyclic groups preferably include rings containing 1 to 3 nitrogen atoms in a 5 - 7-membered ring, specifically a pyridine ring, pyrimidinyl ring, pyrazinyl ring, imidazolyl ring, pyridazinyl ring, etc., and these heterocyclic rings may be also substituted with the substituents as mentioned above. The novel benzoxazepine derivative represented by the above formula (I), and its pharmacologically acceptable salts (e.g. hydrochloride, nitrate, sulfate, oxalate, phosphate, methanesulfonate, hydrobromide, acetate, succinate, malonate, tartrate, maleate, fumarate, lactate, citrate), may be administered alone as such, but can be administered orally or parenterally in a desired dosage form (e.g. tablets, capsules, powders, liquid formulations, injections, suppositories) by mixing with pharmacologically acceptable conventional additives such as carriers, excipients, and vehicles. Examples of such diluents or carriers are polyvinyl pyrrolidone, gum arabic, gelatin, sorbitol, cyclodextrin, tragacanth gum, magnesium stearate, talc, polyethylene glycol, polyvinyl alcohol, silica, lactose, crystalline cellulose, sugar, starch, calcium phosphate, vegetable oil, calcium carboxymethyl cellulose, sodium lauryl sulfate, water, ethanol, glycerol, mannitol, and syrup. The concentration of the compound of the formula (I) in such a pharmaceutical preparation is not particularly limited, but is generally about 1 to 100% by weight of the preparation, preferably about 10 to 100% by weight. Also, the dose thereof is not particularly limited, but is suitably 0.1 to 1000 mg/day/person, preferably 1 to 500 mg/day/person, and the dosage number is generally 1 to 4 times per day. EXAMPLES The present invention is now described with reference to, the following Examples and Test Examples. First, syntheses of the intermediate compounds are shown in Examples 1 to 18 and those of the active compounds are shown in Examples 19 to 93. Example 1 Synthesis of 4-(3-chloropropyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-5-one One gram of 2,3,4,5-tetrahydro-1,4-benzoxazepin-5-one was dissolved in 50 ml of dioxane and 5 ml of dimethyl sulfoxide, and 368 mg (1.5 equivalent) of 60% sodium hydride was added, followed by heating at 110°C for one hour while stirring. After cooling, 1.82 ml (3 equivalents) of 1-bromo-3-chloropropane was added to the reaction mixture obtained, and the mixture was stirred at room temperature for 17 hours. Dioxane was evaporated from the reaction mixture obtained, ice-water was added, and the mixture was extracted with ether. The ether extract was washed three times with aqueous sodium chloride, and dried over anhydrous magnesium sulfate. Then the ether solution was concentrated, and the residue was developed with hexane-ethyl acetate (6:4) by silica gel column chromatography to give 1.21 g of the desired compound (yield 83%). Example 2 Synthesis of 4-(3-bromopropyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 100 mg amount of 2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 10 ml of dimethylformamide, and after ice-cooling, 0.172 ml (3 equivalents) of 1,3-dibromopropane and 27.1 mg (1.2 equivalents) of 60% sodium hydride were added, followed by stirring under ice-cooling for one hour. The reaction mixture obtained was poured into an aqueous citric acid under ice-cooling and extracted with ether, and after washing with aqueous sodium chloride, the mixture was dried over anhydrous mangesium sulfate. The ether solution was concentrated, and the residue was developed with hexane-ethyl acetate (8:2) by silica gel column chromatography, to give 79.8 mg of the desired compound (yield 47%). Example 3 Synthesis of 4-(3-bromopropyl)-7-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione An 828 mg amount of 7-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 20 ml of dimethylformamide, 1.62 g (2 equivalents) of 1,3-dibromopropane were added, and after ice-cooling, 240 mg (1.5 equivalents) of 60% sodium hydride was added, followed by stirring under ice-cooling for one hour. The reaction treatment and purification were conducted as in Example 2, to give 280 mg of the desired compound (yield 21.3%). Example 4 Synthesis of 4-(3-bromopropyl)-8-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 764 mg amount of 8-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 20 ml of dimethylformamide, 1.62 mg (2 equivalents) of 1,3-dibromopropane was added, and after ice-cooling, 240 mg (1.5 equivalents) of 60% sodium hydride was added, followed by stirring at room temperature for 30 minutes. The reaction treatment and purification were conducted as in Example 2, to give 417 mg of the desired compound (yield 33.4%). Example 5 Synthesis of 4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-5-one To a solution of 2 g of 2,3,4,5-tetrahydro-1,4-benzoxazepin-5-one dissolved in 100 ml of dioxane and 10 ml of dimethyl sulfoxide, 736 mg (1.5 equivalents) of 60% sodium hydride was added, and the mixture was heated at 110°C for 30 minutes while stirring. The reaction mixture was ice-cooled, and then 4.49 ml (3 equivalents) of 1,4-dibromobutane was added, followed by stirring at room temperature for 2 hours. The reaction treatment and purification were conducted as in Example 1, to give 2.56 g of the desired product (yield 70%). Example 6 Synthesis of 4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzoxazepin-3-one To a solution of 500 mg of 2,3,4,5-tetrahydro-1,4-benzoxazepin-3-one dissolved in 50 ml of dioxane and 5 ml of dimethyl sulfoxide, 184 mg (1.5 equivalents) of 60% sodium hydride was added, and the mixture was heated at room temperature for 30 minutes while stirring. To the reaction mixture were added 1.12 ml (3 equivalents) of 1,4-dibromobutane and 5 ml of dimethylformamide, and the mixture was stirred at room temperature for 3 hours. Then to the reaction mixture obtained was added ice-water, the mixture was extracted with ether, and the extract was washed with aqueous sodium chloride, followed by drying over anhydrous magnesium sulfate. The ether solution was concentrated, and the residue was developed with hexane-ethyl acetate (7:3) by silica gel column chromatography, to give 504 mg of the desired compound (yield 55.1%). Example 7 Synthesis of 4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 10 g amount of 2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 100 ml of dimethylformamide, and after ice-cooling, 20.7 ml (3 equivalents) of 1,4-dibromobutane and 2.71 g (1.2 equivalents) of 60% sodium hydride were added, followed by stirring under ice-cooling for 1.5 hours. The reaction treatment and purification were conducted as in Example 2, to give 10.3 g of the desired compound (yield 58%). Example 8 Synthesis of 4-(4-bromobutyl)-7-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 414 mg amount of 7-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 10 ml of dimethylformamide, and after ice-cooling, 120 mg (1.5 equivalents) of 60% sodium hydride was added. After stirring for 10 minutes, 860 mg (2 equivalents) of 1,4-bromobutane was added, followed by stirring at room temperature for one hour. The reaction treatment and purification were conducted as in Example 2, to give 345 mg of the desired product (yield 50.4%). Example 9 Synthesis of 8-chloro-4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 1.5 g amount of 8-chloro-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 40 ml of dimethylformamide, and after ice-cooling, 1.30 ml (1.5 equivalents) of 1,4-dibromobutane and 340 mg (1.2 equivalents) of 60% sodium hydride were added, followed by stirring under ice-cooling for 30 minutes. The reaction treatment and purification were conducted as in Example 2, to give 920 mg of the desired compound (yield 37%). Example 10 Synthesis of 4-(4-bromobutyl)-8-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione To a solution of 764 mg of 8-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione dissolved in 20 ml of dimethylformamide 1.72 g (2 equivalents) of 1,4-dibromobutane was added, and after ice-cooling, 240 mg (1.5 equivalents) of 60% sodium hydride was added, followed by stirring at room temperature for 1.5 hours. The reaction treatment and purification were conducted as in Example 2, to give 880 mg of the desired compound (yield 67.5%). Example 11 Synthesis of 8-methoxy-4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione One gram of 8-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 30 ml of dimethylformamide, and after ice-cooling, 1.77 ml (3 equivalents) of 1,4-dibromobutane and 232 mg (1.2 equivalents) of 60% sodium hydride were added, followed by stirring under ice-cooling for 1.5 hours. The reaction treatment and purification were conducted as in Example 2, to give 1.25 g of the desired compound (yield 76%). Example 12 Synthesis of 6-methoxy-4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 204 mg amount of 6-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 20 ml of dimethylformamide, and after ice-cooling, 0.361 mg (3 equivalents) of 1,4-dibromobutane and 47.4 mg (1.2 equivalents) of 60% sodium hydride were added, followed by stirring under ice-cooling for 1.5 hours. The reaction treatment and purification were conducted as in Example 2, to give 117 mg of the desired compound (yield 35%). Example 13 Synthesis of 6-benzyloxy-4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 410 mg amount of 6-benzyloxy-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 40 ml of dimethylformamide, and after ice-cooling, 0.265 ml (1.5 equivalents) of 1,4-dibromobutane and 69.5 mg (1.2 equivalents) of 60% sodium hydride were added, followed by stirring under ice-cooling for one hour. The reaction treatment and purification were conducted as in Example 2, to give 450 mg of the desired compound (yield 74%). Example 14 Synthesis of 7-nitro-4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 56.3 mg amount of 7-nitro-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 10 ml of dimethylformamide, and after ice-cooling, 0.0927 ml (3 equivalents) of 1,4-dibromobutane and 12.2 mg (1.2 equivalents) of 60% sodium hydride were added, followed by stirring at room temperature for 2 hours under ice-cooling. The reaction treatment and purification were conducted as in Example 2, to give 16.4 mg of the desired compound (yield 18%). Example 15 Synthesis of 7-methoxycarbonyl-4-(4-bromobutyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 125 mg amount of 7-methoxycarbonyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 10 ml of dimethylformamide, and, after ice-cooling, 0.193 ml (3 equivalents) of 1,4-dibromobutane, and 25.3 mg (1.2 equivalents) of 60% sodium hydride were added, followed by stirring under ice-cooling for 1 hour. The reaction treatment and purification were conducted as in Example 2, to give 124 mg of the desired compound (yield 63%). Example 16 Synthesis of 4-(5-bromopentyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 300 mg amount of 2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 30 ml of dimethylformamide, and after ice-cooling, 0.693 ml (3 equivalents) of 1,5-dibromopentane and 81.4 mg (1.2 equivalents) of 60% sodium hydride were added, followed by stirring under ice-cooling for 30 minutes. The reaction treatment and purification were conducted as in Example 2, to give 238 mg of the desired compound (yield 43%). Example 17 Synthesis of 4-(5-bromopentyl)-7-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 621 mg amount of 7-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 10 ml of dimethylformamide, and 1.38 g (2 equivalents) of 1,5-bromopentane were added, and after ice-cooling, 180 mg (1.5 equivalents) of 60% sodium hydride was added, followed by stirring at room temperature for 4 hours. The reaction treatment and purification were conducted as in Example 2, to give 396 mg of the desired compound (yield 37.1%). Example 18 Synthesis of 4-(5-bromopentyl)-8-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 764 mg amount of 8-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione was dissolved in 20 ml of dimethylformamide, and 2.07 g (2 equivalents) of 1,5-dibromopentane was added, and after ice-cooling, 240 mg (1.5 equivalents) of 60% sodium hydride was added, followed by stirring at room temperature for 30 minutes. The reaction treatment and purification were conducted as in Example 2, to give 680 mg of the desired compound (yield 50.0%). The physical data of the compounds obtained in the above-mentioned Examples 1 to 18 is shown in Table 1. Example 19 Synthesis of 4-(3-(4-(2-pyridyl)piperazinyl)propyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-5-one To a solution of 289 mg of the compound of Example 1 dissolved in 30 ml of dioxane, 0.937 ml (5 equivalents) of 1-(2-pyridyl)piperazine was added, and the mixture was heated under reflux for 17 hours. The dioxane was evaporated, aqueous sodium hydrogen carbonate was added, and the mixture was extracted with methylene chloride. The extract was washed with saturated aqueous sodium chloride, and then dried over anhydrous magnesium sulfate. Then the methylene chloride solution was concentrated, and the residue was developed with methylene chloride-methanol (97:3) by silica gel column chromatography, to give 320 mg of the desired product (yield 73%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from ethanol-ether. Example 20 Synthesis of 4-(3-(4-(3-chlorophenyl)piperazinyl)propyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-5-one To a solution of 300 mg of the compound of Example 1 dissolved in 30 ml of dioxane, 1.23 g (5 equivalents) of 1-(3-chlorophenyl)piperazine was added, and the mixture was heated under reflux for 17 hours. The reaction treatment and purification were conducted as in Example 19, to give 380 mg of the desired compound (yield 76%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from ethanol-ether. Example 21 Synthesis of 4-(3-(4-(2-pyridyl)piperazinyl) propyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 50 mg amount of the compound of Example 2 was dissolved in 10 ml of dioxane, and 0.133 ml of (5 equivalents) of 1-(2-pyridyl)piperazine was added, followed by stirring at 100°C for 17 hours. The reaction treatment was conducted as in Example 19, and developed with ethyl acetate-hexane (3:1) by silica gel column chromatography, to give 48.0 mg of the desired compound (yield 75%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 22 Synthesis of 4-(3-(4-(2-pyrimidinyl)piperazinyl)propyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 60 mg amount of the compound of Example 2 was dissolved in 10 ml of dioxane, and 168 mg (5 equivalents) of 1-(2-pyrimidinyl) piperazine was added, followed by stirring at 100°C for 17 hours. After the post-treatment conducted as in Example 19 and the purification as in Example 21, 61.6 mg of the desired compound was obtained (yield 80%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 23 Synthesis of 7-methoxy-4-(3-(2-pyridyl)piperazinyl)propyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 98 mg amount of the compound of Example 3 was dissolved in 10 ml of dioxane, and 147 mg (3 equivalents) of 1-(2-pyridyl)piperazine was added, followed by stirring at 100°C for 20 hours. The reaction mixture was poured into water and extracted with ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate, and the solvent was evaporated under a reduced pressure. The residue was developed with ethyl acetate by silica gel column chromatography, to give 88 mg of the desired compound (yield 71.5%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 24 Synthesis of 7-methoxy-4-(3-(2-pyrimidinyl)piperazinyl)propyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 98 mg amount of the compound of Example 3 was dissolved in 10 ml of dioxane, and 147 mg (3 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by stirring at 100°C for 20 hours. The reaction treatment and purification were conducted as in Example 23, to give 107 mg of the desired compound (yield 86.8%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 25 Synthesis of 8-methyl-4-(3-(2-pyridyl)piperazinyl) propyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 125 mg amount of the compound of Example 4 was dissolved in 10 ml of dioxane, and 196 mg (3 equivalents) of 1-(2-pyridyl)piperazine was added, followed by refluxing for 48 hours. The reaction treatment and purification were conducted as in Example 23, to give 113 mg of the desired compound (yield 71.7%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 26 Synthesis of 8-methyl-4-(3-(2-pyrimidinyl)piperazinyl)propyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 125 mg amount of the compound of Example 4 was dissolved in 10 ml of dioxane, and 196 mg (3 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by stirring at 90 to 100°C for 48 hours. The reaction treatment and purification were conducted as in Example 23, to give 133 mg of the desired compound (yield 84.1%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 27 Synthesis of 4-(4-(4-(2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-5-one A 300 mg amount of the compound of Example 5 was dissolved in 30 ml of dioxane, and 0.782 ml (5 equivalents) of 1-(2-pyridyl)piperazine was added, followed by heating under reflux for 2 hours. The reaction treatment and the purification were conducted as in Example 19, to give 342 mg of the desired compound (yield 89.4%). Example 28 Synthesis of 4-(4-(4-(2-pyrimidinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-5-one A 300 mg amount of the compound of Example 5 was dissolved in 30 ml of dioxane, and 825 mg (5 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by heating under reflux for 17 hours. The reaction treatment and the purification were conducted as in Example 19, to give 275 mg of the desired compound (yield 71.7%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from ethanol-ether. Example 29 Synthesis of 4-(4-(4-(3-chlorophenyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-5-one A 300 mg amount of the compound of Example 5 was dissolved in 30 ml of dioxane, and 986 mg (5 equivalents) of 1-(3-chlorophenyl)piperazine was added, followed by heating under reflux for 4 hours. The reaction treatment and purification were conducted as in Example 19, to give 399 mg of the desired compound (yield 96%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from ethanol-ether. Example 30 Synthesis of 4-(4-(4-(2-methoxyphenyl)piperazinyl)butyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-5-one A 300 mg amount of the compound of Example 5 was dissolved in 30 ml of dioxane, and 0.902 ml (5 equivalents) of 1-(2-methoxyphenyl)piperazine was added, followed by heating under reflux for 2 hours. The reaction treatment and purification were conducted as in Example 19, to give 387 mg of the desired compound (yield 94%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from ethanol-ether. Example 31 Synthesis of 4-(4-(4-(2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3-one A 100 mg amount of the compound of Example 6 was dissolved in 10 ml of dioxane, and 0.26 ml (5 equivalents) of 1-(2-pyridyl)piperazine was added, followed by heating under reflux for 11 hours. The reaction treatment and purification were conducted as in Example 19, to give 125 mg of the desired compound (yield 98%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 32 Synthesis of 4-(4-(4-(2-pyrimidinyl)piperazinyl)butyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-3-one A 100 mg amount of the compound of Example 6 was dissolved in 10 ml of dioxane, and 275 mg (5 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by heating under reflux for 17 hours. The reaction treatment and purification were conducted as in Example 19, to give 118 mg of the desired compound (yield 92.3%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 33 Synthesis of 4-(4-(4-(3-chlorophenyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-one A 100 mg amount of the compound of Example 6 was dissolved in 10 ml of dioxane, and 330 mg (5 equivalents) of 1-(3-chlorophenyl)piperazine was added, followed by heating under reflux for 11 hours. The reaction treatment and purification were conducted as in Example 19, to give 137 mg of the desired compound (yield 99%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from ethanol-ether. Example 34 Synthesis of 4-(4-(4-phenylpiperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 156 mg amount of the compound of Example 7 was dissolved in 10 ml of dioxane, and 243 mg (3 equivalents) of phenylpiperazine was added, followed by stirring at 90 to 100°C for 12 hours. The reaction treatment and purification were conducted as in Example 23, to give 180 mg of the desired compound (yield 91.5%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ethyl acetate. Example 35 Synthesis of 4-(4-(4-(2-fluorophenyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 100 mg amount of the compound of Example 7 was dissolved in 10 ml of dioxane, and 173 mg (3 equivalents) of 1-(2-fluorophenyl)piperazine was added, followed by heating while stirring under reflux for 5 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 126 mg of the desired compound (yield 96%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 36 Synthesis of 4-(4-(4-(2-chlorophenyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 100 mg amount of the compound of Example 7 was dissolved in 10 ml of dioxane, and 315 mg (5 equivalents) of 1-(2-chlorophenyl)piperazine was added, followed by heating under reflux for 17 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 114 mg of the title compound (yield 83%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 37 Synthesis of 4-(4-(4-(2-methoxyphenyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-1,3-dione A 174 mg amount of the compound of Example 7 was dissolved in 20 ml of dioxane, and 0.5 ml of 1-(2-methoxyphenyl)piperazine was added, followed by heating under reflux for 6 hours. The post-treatment was conducted as in Example 19 and the purification as in Example 21, to give 198 mg of the desired compound (yield 84%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 38 Synthesis of 4-(4-(4-(2-hydroxyphenyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 100 mg amount of the compound of Example 7 was dissolved in 20 ml of dioxane, and 171 mg (3 equivalents) of 1-(2-hydroxyphenyl)piperazine was added, followed by heating under stirring at 100°C for 17 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 128 mg of the desired compound (yield 98%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 39 Synthesis of 4-(4-(4-(3-chlorophenyl)piperazinyl)butyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 200 mg amount of the compound of Example 7 was dissolved in 20 ml of dioxane, and 631 mg (5 equivalents) of 1-(3-chlorophenyl)piperazine was added, followed by heating under reflux for 17 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 266 mg of the desired compound (yield 97%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 40 Synthesis of 4-(4-(4-(3-methoxyphenyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 68.4 mg amount of the compound of Example 7 was dissolved in 10 ml of dioxane, and 131 mg (3 equivalents) of 1-(3-methoxyphenyl)piperazine was added, followed by heating under stirring at 100°C for 17 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 82.1 mg of the desired compound (yield 88%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 41 Synthesis of 4-(4-(4-(3-methylphenyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 100 mg amount of the compound of Example 7 was dissolved in 20 ml of dioxane, and 169 mg (3 equivalents) of 1-(3-methylphenyl)piperazine was added, followed by heating under stirring at 100°C for 10 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 127 mg of the desired compound (yield 97%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 42 Synthesis of 4-(4-(4-(3-trifluoromethylphenyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 100 mg amount of the compound of Example 7 was dissolved in 10 ml of dioxane, and 228 mg (3 equivalents) of 1-(3-trifluoromethylphenyl) piperazine was added, followed by heating under stirring at 100°C for 17 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 136 mg of the desired compound (yield 91%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 43 Synthesis of 4-(4-(4-(4-fluorophenyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 100 mg amount of the compound of Example 7 was dissolved in dioxane, and 151 mg (3 equivalents) of 1-(4-fluorophenyl)piperazine was added, followed by heating under stirring at 100°C for 17 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 122 mg of the desired compound (yield 99%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 44 Synthesis of 4-(4-(4-(4-chlorophenyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 100 mg amount of the compound of Example 7 was dissolved in 10 ml of dioxane, and 189 mg (3 equivalents) of 1-(4-chlorophenyl)piperazine was added, followed by heating while stirring under reflux for 15 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 113 mg of the desired compound (yield 83%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 45 Synthesis of 4-(4-(4-(4-methoxyphenyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 94.1 mg amount of the compound of Example 7 was dissolved in 10 ml of dioxane, and 299 mg (5 equivalents) of 1-(4-methoxyphenyl)piperazine was added, followed by heating under reflux for 6 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 104 mg of the desired compound (yield 81%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 46 Synthesis of 4-(4-(4-(4-acetylphenyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 100 mg amount of the compound of Example 7 was dissolved in 10 ml of dioxane, and 216 mg (3 equivalents) of 94% 4-piperazinoacetophenone was added, followed by heating under stirring at 100°C for 17 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 101 mg of the desired compound (yield 72%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 47 Synthesis of 4-(4-4-(2-(pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 200 mg amount of the compound of Example 7 was dissolved in 20 ml of dioxane, and 0.498 ml (5 equivalents) of 1-(2-pyridyl)piperazine was added, followed by heating under reflux for 17 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 196 mg of the desired compound (yield 77.6%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 48 Synthesis of 4-(4-(4-(3-chloro-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 156 mg amount of the compound of Example 7 was dissolved in 10 ml of dioxane, and 295 mg (3 equivalents) of 1-(3-chloro-2-pyridyl)piperazine was added, followed by heating under stirring at 100°C for 24 hours. The reaction treatment and purification were conducted as in Example 23, to give 225 mg of the desired compound (yield 98.0%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 49 Synthesis of 4-(4-(4-(3-nitro-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 156 mg amount of the compound of Example 7 was dissolved in 10 ml of dioxane, and 312 mg (3 equivalents) of 1-(3-nitro-2-pyridyl)piperazine was added, followed by refluxing for 23 hours. The reaction treatment and purification were conducted as in Example 23, to give 210 mg of the desired compound (yield 95.5%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 50 Synthesis of 4-(4-(4-(3-cyano-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 156 mg amount of the compound of Example 7 was dissolved in 10 ml of dioxane, and 282 mg (3 equivalents) of 1-(3-cyano-2-pyridyl)piperazine was added, followed by refluxing for 20 hours. The reaction treatment and purification were conducted as in Example 23, to give 190 mg of the desired compound (yield 90.6%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 51 Synthesis of 4-(4-(4-(3-amino-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 94 mg amount of the compound of Example 7 was dissolved in 6 ml of dioxane, and 160 mg (3 equivalents) of 1-(3-amino-2-pyridyl)piperazine was added, followed by refluxing for 48 hours. The reaction treatment and purification were conducted as in Example 23, to give 94 mg of the desired compound (yield 76.5%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from ethanol-ether. Example 52 Synthesis of 4-(4-(4-(2-pyrimidinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 500 mg amount of the compound of Example 7 was dissolved in 50 ml of dioxane, and 1.31 g (5 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by heating under reflux for 17 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 602 mg of the desired compound (yield 95.1%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 53 Synthesis of 7-methoxy-4-(4-(4-(2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 100 mg amount of the compound of Example 8 was dissolved in 10 ml of dioxane, and 147 mg (3 equivalents) of 1-(2-pyridyl)piperazine was added, followed by heating under stirring at 90°C for 48 hours. The reaction treatment and purification were conducted as in Example 23, to give 108 mg of the desired compound (yield 84.8%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 54 Synthesis of 7-methoxy-4-(4-(4-(3-chloro-2-pyridyl)-piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 137 mg amount of the compound of Example 8 was dissolved in 10 ml of dioxane, and 236 mg (3 equivalents) of 1-(3-chloro-2-pyridyl)piperazine was added, followed by refluxing for 40 hours. The reaction treatment and purification were conducted as in Example 23, to give 209 mg of the desired compound (yield 99.1%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 55 Synthesis of 7-methoxy-4-(4-(4-(3-nitro-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 137 mg amount of the compound of Example 8 was dissolved in 10 ml of dioxane, and 249 mg (3 equivalents) of 1-(3-nitro-2-pyridyl)piperazine was added, followed by refluxing for 40 hours. The reaction treatment and purification were conducted as in Example 23, to give 182 mg of the desired compound (yield 96.9%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 56 Synthesis of 7-methoxy-4-(4-(4-(3-cyano-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 138 mg amount of the compound of Example 8 was dissolved in 10 ml of dioxane, and 235 mg (3 equivalents) of 1-(3-cyano-2-pyridyl)piperazine was added, followed by refluxing for 40 hours. The reaction treatment and purification were conducted as in Example 23, to give 182 mg of the desired compound (yield 98.5%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 57 Synthesis of 7-methoxy-4-(4-(4-(3-amino-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 244 mg amount of the compound of Example 55 was dissolved in 10 ml of ethanol, and 50 mg of platinum dioxide was added to carry out hydrogenation for 0.5 hour. The reaction mixture obtained was filtered, the filtrate was evaporated under a reduced pressure, and the residue was eluted with ethyl acetate by silica gel column chromatography, to give 179 mg of the desired compound (yield 83.4%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from ethanol-ether. Example 58 Synthesis of 7-methoxy-4-(4-(4-(2-pyrimidinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 100 mg amount of the compound of Example 8 was dissolved in 10 ml of dioxane, and 147 mg (3 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by stirring at 90°C for 48 hours. The reaction treatment and purification were conducted as in Example 23, to give 116 mg of the desired compound (yield 90.9%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 59 Synthesis of 8-chloro-4-(4-(4-(2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 98.0 mg amount of the compound of Example 9 was dissolved in 10 ml of dioxane, and 0.132 ml (3 equivalents) of 1-(2-pyridyl)piperazine was added, followed by heating under stirring at 100°C for 10 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 86.8 mg of the desired compound (yield 72%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 60 Synthesis of 8-chloro-4-(4-(4-(3-chloro-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 102 mg amount of the compound of Example 9 was dissolved in 10 ml of dioxane, and 58.1 mg (1 equivalent) of 1-(3-chloro-2-pyridyl)piperazine and 122 mg (3 equivalent) of potassium carbonate were added, followed by heating under reflux for 2 days. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 86.3 mg of the desired compound (yield 63%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followd by recrystallization from methylene chloride-ether. Example 61 Synthesis of 8-chloro-4-(4-(4-(3-nitro-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 121 mg amount of the compound of Example 9 was dissolved in 15 ml of dioxane, and 218 mg (3 equivalents) of 1-(3-nitro-2-pyridyl)piperazine was added, followed by heating under reflux for 5 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 133 mg of the desired compound (yield 80%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 62 Synthesis of 8-chloro-4-(4-(4-(3-cyano-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 102 mg amount of the compound of Example 9 was dissolved in 10 ml of dioxane, and 55.3 mg (1 equivalent) of 1-(3-cyano-2-pyridyl)piperazine and 122 mg (3 equivalents) of potassium carbonate were added, followed by heating under reflux for 2 days. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 88.2 mg of the desired compound (yield 66%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 63 Synthesis of 8-chloro-4-(4-(4-(3-amino-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 104 mg amount of the compound of Example 9 was dissolved in 10 ml of dioxane, and 160 mg (3 equivalents) of 1-(3-amino-3-pyridyl)piperazine was added, followed by heating under reflux for 17 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 116 mg of the desired compound (yield 87%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 64 Synthesis of 8-chloro-4-(4-(4-(2-pyrimidinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 98.0 mg amount of the compound of Example 9 was dissolved in 10 ml of dioxane, and 139 mg (3 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by heating under reflux for 4 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 88.9 mg of the desired compound (yield 73%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 65 Synthesis of 8-methyl-4-(4-(4-(2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 130 mg amount of the compound of Example 10 was dissolved in 10 ml of dioxane, and 196 mg (3 equivalents) of 1-(2-pyridyl)piperazine was added, followed by stirring at 90 to 100°C for 48 hours. The reaction treatment and purification were conducted as in Example 23, to give 149 mg of the desired compound (yield 91.2%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 66 Synthesis of 8-methyl-4-(4-(4-(3-chloro-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 130 mg amount of the compound of Example 10 was dissolved in 10 ml of dioxane, and 236 mg (3 equivalents) of 1-(3-chloro-2-pyridyl)piperazine was added, followed by refluxing for 20 hours. The reaction treatment and purification were conducted as in Example 23, to give 172 mg of the desired compound (yield 97.1%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 67 Synthesis of 8-methyl-4-(4-(4-(3-nitro-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 130 mg amount of the compound of Example 10 was dissolved in 10 ml of dioxane, and 249 mg (3 equivalents) of 1-(3-nitro-2-pyridyl)piperazine was added, followed by refluxing for 20 hours. The reaction treatment and purification were conducted as in Example 23, to give 197 mg of the desired compound (yield 97.5%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 68 Synthesis of 8-methyl-4-(4-(4-(3-cyano-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 130 mg amount of the compound of Example 10 was dissolved in 10 ml of dioxane, and 225 mg (3 equivalents) of 1-(3-cyano-2-pyridyl)piperazine was added, followed by refluxing for 20 hours. The reaction treatment and purification were conducted as in Example 23, to give 207 mg of the desired compound (yield 96.2%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 69 Synthesis of 8-methyl-4-(4-(4-(3-amino-2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione Using 249 mg of the compound of Example 67, the reaction treatment and purification were conducted as in Example 57, to give 101 mg of the desired compound (yield 48.9%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from ethanol-ether. Example 70 Synthesis of 8-methyl-4-(4-(4-(2-pyrimidinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 130 mg amount of the compound of Example 10 was dissolved in 10 ml of dioxane, and 196 mg (3 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by stirring at 90 to 100°C for 48 hours. The reaction treatment and purifcation were conducted as in Example 23, to give 155 mg of the desired compound (yield 94.7%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 71 Synthesis of 8-methoxy-4-(4-(4-(2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 106 mg amount of the compound of Example 11 was dissolved in 10 ml of dioxane, and 0.144 ml (3 equivalents) of 1-(2-pyridyl)piperazine was added, followed by heating under reflux for 5 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 81.8 mg of the desired compound (yield 62%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 72 Synthesis of 8-methoxy-4-(4-(4-(2-pyrimidinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 200 mg amount of the compound of Example 11 was dissolved in 20 ml of dioxane, and 288 mg (3 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by heating under reflux for 5 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 141 mg of the desired compound (yield 57%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 73 Synthesis of 6-methoxy-4-(4-(4-(2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 55 mg amount of the compound of Example 12 was dissolved in 10 ml of dioxane, and 0.0749 ml (3 equivalents) of 1-(2-pyridyl)piperazine was added, followed by heating under reflux for 7 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 64.8 mg of the desired compound (yield 95%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Exampel 74 Synthesis of 6-methoxy-4-(4-(4-(2-pyrimidinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione. A 60.8 mg amount of the compound of Example 12 was dissolved in 10 ml of dioxane, and 87.4 mg (3 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by heating under reflux for 7 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 61.0 mg of the desired compound (yield 81%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 75 Synthesis of 6-benzyloxy-4-(4-(4-(2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 229 mg amount of the compound of Example 13 was dissolved in 20 ml of dioxane, and 0.255 ml (3 equivalents) of 1-(2-pyridyl)piperazine was added, followed by heating under reflux for 7 hours. Next, the dioxane was evaporated, aqueous sodium hydrogen carbonate was added, and the mixture was extracted with methylene chloride. The extract was washed with saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, the methylene chloride solution was then concentrated, and the residue was developed with ethyl acetate by silica gel column chromatography to give 210 mg of the desired compound (yield 77%). Example 76 Synthesis of 6-benzyloxy-4-(4-(4-(2-pyrimidinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 202 mg amount of the compound of Example 13 was dissolved in 20 ml of dioxane, and 242 mg (3 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by heating under reflux for 7 hours. The reaction treatment and purification were conducted as in Example 75, to give 195 mg of the desired compound (yield 79%). The maleic acid salt was obtained in a conventional manner. Example 77 Synthesis of 6-hydroxy-4-(4-(4-(2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione To 20.5 mg of 10% palladium-carbon, 5 ml of ethyl acetate was added, and after the atmosphere in the reaction vessel was replaced with hydrogen and the mixture was stirred at room temperature for 30 minutes, a solution of 205 mg of the compound of Example 75 dissolved in 5 ml of ethyl acetate was added, followed by stirring at room temperature for 11 hours. The reaction mixture was filtered, the solvent was evaporated from the filtrate, and the residue was developed with hexane-ethyl acetate (1:2) by silica gel column chromatography, to give 140 mg of the desired compound (yield 83%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 78 Synthesis of 6-hydroxy-4-(4-(4-(2-pyrimidinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione To 23.6 mg of 10% palladium-carbon, 5 ml of ethyl acetate was added, and after the atmosphere in the reaction vessel was replaced with hydrogen and the mixture was stirred at room temperature for 30 minutes, a solution of 236 mg of the compound of Example 76 dissolved in 5 ml of ethyl acetate was added, followed by stirring at room temperature for 17 hours. The reaction treatment and purification were conducted as in Example 77, to give 160 mg of the desired compound (yield 83%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 79 Synthesis of 7-nitro-4-(4-(4-(2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 7.2 mg amount of the compound of Example 7 was dissolved in 3 ml of dioxane, and 0.00937 ml (3 equivalents) of 1-(2-pyridyl)piperazine was added, followed by heating while stirring under reflux for 2 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 2.7 mg of the desired compound (yield 30%). The maleic acid salt was obtained by forming the maleic acid salt in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 80 Synthesis of 7-nitro-4-(4-(4-(2-pyrimidinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 8.2 mg amount of the compound of Example 14 was dissolved in 3 ml of dioxane, and 11.3 mg (3 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by heating while stirring under reflux for 4 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 5.5 mg of the desired compound (yield 54%). The maleic acid salt was obtained by forming the maleic acid salt in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 81 Synthesis of 7-methoxycarbonyl-4-(4-(4-(2-pyridyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 60 mg amount of the compound of Example 15 was dissolved in 10 ml of dioxane, and 0.0751 ml (3 equivalents) of 1-(2-pyridyl)piperazine was added, followed by heating while stirring under reflux for 8 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 63.4 mg of the desired compound (yield 87%). The citric acid salt was obtained by forming the citric acid salt in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 82 Synthesis of 7-methoxycarbonyl-4-(4-(4-(2-pyrimidinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 60 mg amount of the compound of Example 15 was dissolved in 10 ml of dioxane, and 79.3 mg (3 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by heating while stirring under reflux for 6 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 53.1 mg of the desired compound (yield 72%). The maleic acid salt was obtained by forming the maleic acid salt in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 83 Synthesis of 4-(4-(4-(4-methoxy-2-pyrimidinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 326 mg amount of the compound of Example 7 was dissolved in 20 ml of dioxane, and a mixture of 580 mg (3 equivalents) of 1-(4-methoxy-2-pyrimidinyl)piperazine and 1-(2-methoxy-4-pyrimidinyl)piperazine (4:1) was added, followed by refluxing for 15 hours. The reaction treatment and purification were conducted as in Example 23, to give 271 mg of the desired compound (yield 70.4%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from ethanol-ether. Example 84 Synthesis of 4-(4-(4-(2-methoxy-4-pyrimidinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione Using the same reaction and purification treatments as in Example 83, 36 mg of the desired product was obtained (yield 8.4%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from ethanol-ether. Example 85 Synthesis of 4-(4-(4-(2-pyrazinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 326 mg amount of the compound of Example 7 was dissolved in 20 ml of dioxane, and 492 mg (3 equivalents) of 1-pyrazinylpiperazine was added, followed by refluxing for 20 hours. The reaction treatment and purification were conducted as in Example 23, to give 270 mg of the desired compound (yield 68.3%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from ethanol-ether. Example 86 Synthesis of 4-(4-(4-(6-chloro-2-pyrazinyl)piperazinyl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 163 mg amount of the compound of Example 7 was dissolved in 10 ml of dioxane, and 298 mg (3 equivalents) of 1-(6-chloro-2-pyrazinyl)piperazine was added, followed by refluxing for 18 hours. The reaction treatment and purification were conducted as in Example 23, to give 194 mg of the desired compound (yield 92.8%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from ethanol-ether. Example 87 Synthesis of 4-(4-(4-(6-methoxy-2-pyrazinyl)piperazinyl)butyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 130 mg amount of the compound of Example 7 was dissolved in 10 ml of dioxane, and 232 mg (3 equivalents) of 1-(6-methoxy-2-pyrazinyl)piperazine was added, followed by stirring at 100°C for 20 hours. The reaction treatment and purification were conducted as in Example 23, to give 158 mg of the desired compound (yield 92.8%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene ethanol-ether. Example 88 Synthesis of 4-(5-(4-(2-pyridyl)piperazinyl)pentyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 70 mg amount of the compound of Example 16 was dissolved in 10 ml of dioxane, and 0.167 ml (5 equivalents) of 1-(2-pyridyl)piperazine was added, followed by heating under stirring at 100°C for 6 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 79.4 mg of the desired compound (yield 91%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 89 Synthesis of 4-(5-(4-(2-pyrimidinyl)piperazinyl) pentyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 70 mg amount of the compound of Example 16 was dissolved in 10 ml of dioxane, and 176 mg (5 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by heating under stirring at 100°C for 6 hours. The reaction treatment was conducted as in Example 19 and purification as in Example 21, to give 69.2 mg of the title compound (yield 79%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 90 Synthesis of 7-methoxy-4-(5-(4-(2-pyridyl)piperazinyl)pentyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 106 mg amount of the compound of Example 17 was dissolved in 10 ml of dioxane, and 147 mg (3 equivalents) of 1-(2-pyridyl)piperazine was added, followed by heating under stirring at 90 to 100°C for 24 hours. The reaction treatment and purification were conducted as in Example 23, to give 106 mg of the desired compound (yield 80.7%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 91 Synthesis of 7-methoxy-4-(5-(4-(2-pyrimidinyl)piperazinyl)pentyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 106 mg amount of the compound of Example 17 was dissolved in 10 ml of dioxane, and 147 mg (3 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by heating under stirring at 90 to 100°C for 24 hours. The reaction treatment and purification were conducted as in Example 23, to give 106 mg of the desired compound (yield 80.5%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 92 Synthesis of 8-methyl-4-(5-(4-(2-pyridyl)piperazinyl)pentyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 136 mg amount of the compound of Example 18 was dissolved in 10 ml of dioxane, and 200 mg (3 equivalents) of 1-(2-pyridyl)piperazine was added, followed by heating under stirring at 90 to 100°C for 24 hours. The reaction treatment and purification were conducted as in Example 23, to give 154 mg of the desired compound (yield 91.7%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 93 Synthesis of 8-methyl-4-(5-(4-(2-pyrimidinyl)piperazinyl)pentyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 136 mg amount of the compound of Example 18 was dissolved in 10 ml of dioxane, and 200 mg (3 equivalents) of 1-(2-pyrimidinyl)piperazine was added, followed by heating under stirring at 90 to 100°C for 24 hours. The reaction treatment and purfication were conducted as in Example 23, to give 140 mg of the desired compound (yield 83.1%). The hydrochloride was obtained by forming the hydrochloride in a conventional manner, followed by recrystallization from methylene chloride-ether. Example 94 Synthesis of 4-(4-(4-(3-acetylamino-2-pyridyl) piperazine-1-yl)butyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-3,5-dione A 340 mg (0.8 mM) amount of the compound of Example 51 was dissolved in 10 ml of methylene chloride, and 252 mg (3.3 mM, 4 equivalent) of pyridine and 163 mg (1.6 mM, 2 equivalent) of acetic anhydride were added, followed by stirring at room temperature for 3 hours. The solvent was distilled off and ethyl acetate was then added. After washing with water, the organic layer was dried over magnesium sulfate (anhydrous). The organic layer was then filtered and the solvent was distilled off. The residue was eluted with ethyl acetate by using a silica-gel chromatography. Thus, 102 mg of the desired compound was obtained (Yield 28%). The physical data of the compounds obtained in Examples 19 to 94 are shown in Table 2. The compound of the present invention exhibits a high affinity for a serotonin receptor and an anti-conflict activity and is useful as a psychotropic agent against an anxiety neurosis, phobic disorder, and obsessive-compulsive disorder, etc. The pharmocological test results are described below. Affinity for Serotonin Receptor (Test Method) The test was conducted according to the method of S.T. Perouka (J. Neurochem., 47 , 529-540 (1986)). To the cerebral cortex enucleated from a Wistar-strain male rat was added 50 mM Tris-HCl (pH 7.7) buffer, and the mixture was homogenized by using Polytron®. The homogenate was centrifuged at 40,000 G for 10 minutes, and to the obtained precipitate was added the same buffer to effect homogenization, followed by incubation at 37°C for 30 minutes. The suspension was centrifuged again at 40,000 G for 10 minutes, and to the obtained precipitate was added the same buffer to effect homogenization, followed by centrifugation at 40,000 G for 10 minutes. To the final obtained precipitate was added 50 mM Tris-HCl (10 µm pargyline, 4 mM CaCl₂ , 0.1% ascorbic acid) (pH 7.4) buffer, to effect homogenization, and the homogenate was used for the binding test. The (³H) 8-OH-DPAT used for the binding test was 0.4 nM, with a protein amount of 0.4 to 0.6 mg/ml, and a total amount of 1 ml. After incubation at 25°C for 30 minutes, the mixture was filtered by a filtration method using a Whatman GF/B filter, and the filter was washed three times with 5 ml of the same buffer. To the filter was added a scintillation cocktail, and a measurement was conducted by a liquid scintillation counter. (Results) As a result of the above test, all the compounds of Examples according to the present invention were found to have a strong affinity at a dose of a µM order or less. Among them, the following compounds have extremely strong affinity at nM order (see Table 3). Compound (Example No.) [³H]8-OH-DPAT IC₅₀ (nM) 27 6.15 30 2.62 36 2.31 39 1.41 43 2.48 48 2.77 52 3.75 54 4.91 58 5.02 59 1.78 64 4.10 65 1.55 70 4.75 72 4.26 83 4.16

Claims: A benzoxazepine derivative having the formula: wherein A and B are both carbonyl groups, or one thereof represents a methylene group and the other a carbonyl group, R represents an aromatic group or a heterocyclic group, which may be substituted, X represents a hydrogen atom, a halogen atom, a C₁ - C₅ lower alkyl group, a C₁ - C₅ lower alkoxy group, a C₇-C₁₁ arylalkoxy group, a hydroxyl group, a nitro group, or an ester group, and n is an integer of 2 to 10; or a salt thereof. A benzoxazepine derivative as claimed in claim 1, wherein A represents a carbonyl group and B represents a carbonyl group or a methylene group. A benzoxazepine derivative of claim 1 or claim 2, wherein R represents a 5 - 7 membered heterocyclic group having 1 to 3 nitrogen atoms or a C₆ - C₁₀ aromatic group, which may be substituted. A benzoxazepine derivative as claimed in claim 2, wherein the heterocyclic group (which may be substituted) is selected from the group consisting of pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, and imidazolyl, or the aromatic group (which may be substituted) is phenyl or naphthyl. A benzoxazepine derivative having the formula: wherein A and B are both carbonyl groups, or one thereof represents a methylene group and the other a carbonyl group, X represents a hydrogen atom, a halogen atom, a C₁ - C₅ lower alkyl group, a C₁ - C₅ lower alkoxy group, a C₇ - C₉ arylalkoxy group, a hydroxyl group, a cyano group, a nitro group or an ester group, Y represents a halogen atom, and n is an integer of 2 to 10, thereof. A benzoxazepine derivative as claimed in claim 5, wherein A represents a carbonyl group and B represents a carbonyl group or a methylene group. A benzoxazepine derivative as claimed in claim 5, wherein Y represent bromine or chlorine. A psychotropic composition comprising a compound according to claim 1 or a pharmacologically acceptable salt thereof, as an active ingredient, and a carrier therefor. An antianxiety pharmaceutical composition of claim 8. A pharmaceutical composition for diseases related to serotonergic neuron system comprising a compound according to claim 1 or a pharmacologically acceptable salt thereof, as an active ingredient, and a carrier therefor. A benzoxazepine derivative according to any one of claims 1 to 4, for pharmaceutical use. Use of a benzoxazepine derivative or a salt thereof according to any one of claims 1 to 4 in the preparation of a medicament for the treatment of psychotic disorder. A use according to claim 12 where the psychotic disorder is anxiety, neurosis, phobic disorder, obsessive-compulsive disorder, psychosomatic disorder, post traumatic stress disorder or depressive neurosis. Use of a benzoxazepine derivative or salt thereof according to any one of claims 1 to 4 in the preparation of a medicament for the treatment of diseases related to the serotonergic neuron system. Use according to claim 14 where the disease related to the serotonergic neuron system is eating disorder, climacteric disorder or infantile autism. A process for preparing a benzoxazepine having the formula (I): wherein A and B are both carbonyl groups, or one thereof represents a methylene group and the other a carbonyl group, R represents an aromatic group or a heterocyclic group, which may be substituted, X represents a hydrogen atom, a halogen atom, a C₁-C₅ lower alkyl group, a C₁-C₅ lower alkoxy group, a C₇-C₁₁ arylalkoxy group, a hydroxyl group, a nitro group, or an ester group, and n is an integer of 2 to 10; or a salt thereof comprising the steps of: reacting a compound having the formula (a): wherein A, B and X are the same as defined above with a compound having the formula (b): Y-(CH₂) n -Y (b) wherein Y represents a halogen atom and n is an integer of 2 to 10 to form a compound having the formula (II): wherein A, B, X, Y and n are the same as defined above; and reacting the compound (II) with a piperazine derivative having the formula (c): to form the compound (I). A process according to claim 16 wherein A represents a carbonyl group and B represents a carbonyl group or a methylene group. A process according to claim 16 or claim 17 wherein R represents a 5 to 7 membered heterocyclic group having 1 to 3 nitrogen atoms, or a C₆-C₁₀ aromatic group which may be substituted. A process according to any one of claims 16 to 18 wherein the heterocyclic group, which may be substituted, is selected from pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl and imidazolyl, or the aromatic ring which may be substituted is phenyl or naphthyl.

Inventors: NOMURA KAYOKO, SHIBATA MAKOTO, TATSUOKA TOSHIO, NOMURA, KAYOKO, SHIBATA, MAKOTO, TATSUOKA, TOSHIO
Applicants: SUNTORY LTD, SUNTORY LIMITED
Application year: 1989
Main classification: C07D267
IPC codes: C07D413, C07D267